The Pfizer and Moderna coronavirus vaccines are highly effective against and prevent illness from common variants of the virus, according to recently released studies.
The vaccine made by Pfizer is effective against the coronavirus variants that originated from the U.K. and South Africa, according to multiple studies released Wednesday that examined real-world vaccinations, The New York Times reported. Moderna reported that an early-stage trial suggested its vaccine is effective against the South African variant and a third variant originating from Brazil when given as a single-dose booster shot.
“At this point in time, we can confidently say that we can use this vaccine, even in the presence of circulating variants of concern,” London School of Hygiene and Tropical Medicine infectious disease researcher Annelies Wilder-Smith told the NYT.
Recent studies indicate that the Pfizer and Moderna coronavirus vaccines may have reduced protection against the South African coronavirus strain, according to reports in the New England Journal of Medicine, raising concerns that they could be less effective against future mutations.
Though both vaccines appeared to generate enough antibodies to neutralize the mutant strain, they both produced fewer antibodies when compared to the original virus. But experts warned that it was unclear just how much protection was needed to neutralize the variant, which scientists believe is more contagious than the original strain.
Few people realize that the Moderna vaccine against COVID-19—which the FDA has finally declared “highly effective,” and which is now being distributed to Americans—has actually been available for nearly a year.
But the government wouldn’t let you take it.
The two coronavirus vaccines that have been approved for emergency use authorization in the U.S. will be able to combat a new, more contagious strain of the virus in the U.K., experts said Monday.
Vaccines made by pharmaceutical companies Pfizer and Moderna will be effective against the new strain, which is “very similar” to previous strains at the genetic level, University of Washington’s Institute for Health Metrics and Evaluation affiliate assistant professor Vin Gupta told CNBC. The Food and Drug Administration has approved both vaccines for emergency use authorization after large-scale human trials showed efficacy of more than 90%.
The nurse who appeared to faint after receiving a COVID-19 vaccine in a viral video has recovered, according to a statement issued by her employer. Tiffany Dover, a nurse at CHI Memorial Hospital, reportedly came close to passing out due to a medical condition unrelated to the vaccination.
The hospital also cited information from the Centers for Disease Control (CDC) website, which stated that fainting sometimes occurs after all types of vaccinations.
The FDA approved Moderna’s coronavirus vaccine for emergency use Friday, making the United States the first country to have approved two safe and effective vaccines against COVID-19.
Its approval follows a key FDA panel’s overwhelming vote Thursday to endorse the vaccine’s safety and efficacy. The Moderna vaccine’s approval means that its distribution could begin within hours, providing hospitals and long-term care facilities across the country thousands of much-needed doses.
The FDA released data Tuesday reaffirming that Moderna’s coronavirus vaccine is safe and effective in preventing severe cases in adults.
The release is a sign that the vaccine is likely to be granted emergency use from the FDA in the coming days, public health officials said, a critical step in ensuring that millions of Americans can be vaccinated as soon as possible. The FDA released similar data regarding Pfizer’s vaccine just days before it was given emergency approval as well.
A total of 5,850 doses of vaccines arrived in Georgia Monday, as part of a “two-dose series.”
According to the Georgia Department of Public Health (DPH), “initial COVID-19 vaccine supply is limited, DPH is following the recommendations of the Centers for Disease Control and Prevention (CDC) and the Advisory Committee on Immunization Practices (ACIP) and prioritizing healthcare personnel and residents of long-term care facilities for vaccination. Vaccine will be given through closed points of dispensing or PODs. These sites include public health clinics, hospitals, long-term care facilities, pharmacies, etc., and are only accessible to individuals in defined priority groups.”
Pharmaceutical company Moderna announced Monday that it will submit its coronavirus vaccine to the federal government for emergency use authorization approval.
Moderna said it would ask the Food and Drug Administration (FDA) for approval after its large-scale human trial concluded and showed the company’s vaccine to have an overall efficacy of 94.1%, according to NBC News. The vaccine was found to be 100% effective in preventing severe cases of coronavirus, according to Moderna.
Many states in the U.S. are hinging their COVID-19 mitigation strategies on the availability of a widely available vaccine. An issue bound to arise is the extremely cold temperatures the most promising experimental vaccines need to be kept at and the logistics of delivering them across the country.
Moderna’s COVID-19 vaccine is estimated to remain stable at standard refrigerator temperatures of 36° to 46°F for 30 days. Longer storage means a required temperature of mRNA-1273 needs -4°F for up to six months.